Video: Interview With Baiju Shah Of BioMotiv
This article was originally published in The Pink Sheet Daily
Executive Summary
In an interview at the recent BioPharm America conference, Shah explains the role that BioMotiv, a self-described accelerator, plays in advancing academic research into private-sector biopharma companies.
You may also be interested in...
Deal Watch: Genzyme Validates Alnylam's Strategy By Partnering On Hemophilia Candidate
Astellas/Chromocell pain therapy collaboration centers on New Jersey biotech's platform technology, which may solve the problem of reproducing Nav1.7 receptors for in vitro assays. Xoma signs preclinical immuno-oncology partnership with Novartis, dimming the focus on Phase III flop for gevokizumab.
Video: Interview With Sarah Frew Of Penn's Center For Innovation
Formerly an executive with Genzyme and TetraLogic, Sarah Frew of the University of Pennsylvania's Center for Innovation spoke with "The Pink Sheet" at BioPharm America about the deal-making atmosphere between academia and private industry.
Video: Interview With Ovid Therapeutics' Jeremy Levin
The former Teva CEO now heads up neuroscience-focused Ovid. At BioPharm America, he discussed the trend of execs moving from large pharmas to smaller companies as well as the business strategy for Ovid.